MedPath

Study of the Effects of an Oral Nitric Oxide Supplement on Blood Pressure in Prehypertensive Adults

Phase 1
Conditions
Prehypertension
Interventions
Dietary Supplement: Nitric Oxide supplement
Dietary Supplement: Placebo
Registration Number
NCT01937754
Lead Sponsor
Neogenis Laboratories
Brief Summary

Oral supplementation of Neo40(TM), a nitrate lozenge, will reduce blood pressure in healthy adults with clinical prehypertension.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Adults between the ages of 18 to 80 years
  • Two blood pressure readings of >/=135/80 mmHg at rest, thus representing prehypertension
  • Informed consent
Exclusion Criteria
  • Existence of any significant internal or cardiovascular disease;
  • Current use of any antihypertensive medication.
  • Inability to give informed consent, or fill out standard questionnaires or inability to follow up clinically.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Nitric Oxide supplementNitric Oxide supplement-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
Reduction in Systolic and Diastolic Blood Pressure Readings30 days

Two blood pressure readings at rest will be taken at baseline and again after thirty days during the follow-up appointment.

Secondary Outcome Measures
NameTimeMethod
Improvement in Functional Capacity30 days

Participant will take a six minute walk test at baseline and again after thirty days during the follow-up appointment. Achieved distances will be measured and recorded.

Trial Locations

Locations (1)

California Medical Institute

🇺🇸

Beverly Hills, California, United States

© Copyright 2025. All Rights Reserved by MedPath